- Home
- RLMD vs DBL Comparison
RLMD vs DBL Comparison
Compare RLMD & DBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLMD
- DBL
- Stock Information
- Founded
- RLMD 2004
- DBL 2011
- Country
- RLMD United States
- DBL United States
- Employees
- RLMD N/A
- DBL N/A
- Industry
- RLMD Biotechnology: Pharmaceutical Preparations
- DBL
- Sector
- RLMD Health Care
- DBL
- Exchange
- RLMD Nasdaq
- DBL Nasdaq
- Market Cap
- RLMD 289.7M
- DBL 292.0M
- IPO Year
- RLMD N/A
- DBL N/A
- Fundamental
- Price
- RLMD $4.22
- DBL $15.32
- Analyst Decision
- RLMD Buy
- DBL
- Analyst Count
- RLMD 2
- DBL 0
- Target Price
- RLMD $5.50
- DBL N/A
- AVG Volume (30 Days)
- RLMD 2.1M
- DBL 61.0K
- Earning Date
- RLMD 11-13-2025
- DBL 01-01-0001
- Dividend Yield
- RLMD N/A
- DBL 8.67%
- EPS Growth
- RLMD N/A
- DBL N/A
- EPS
- RLMD N/A
- DBL N/A
- Revenue
- RLMD N/A
- DBL N/A
- Revenue This Year
- RLMD N/A
- DBL N/A
- Revenue Next Year
- RLMD N/A
- DBL N/A
- P/E Ratio
- RLMD N/A
- DBL N/A
- Revenue Growth
- RLMD N/A
- DBL N/A
- 52 Week Low
- RLMD $0.24
- DBL $13.75
- 52 Week High
- RLMD $5.12
- DBL $15.70
- Technical
- Relative Strength Index (RSI)
- RLMD 72.46
- DBL 40.68
- Support Level
- RLMD $3.81
- DBL $15.14
- Resistance Level
- RLMD $5.12
- DBL $15.33
- Average True Range (ATR)
- RLMD 0.55
- DBL 0.12
- MACD
- RLMD 0.05
- DBL -0.02
- Stochastic Oscillator
- RLMD 64.44
- DBL 25.58
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.